{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:48:46Z","timestamp":1790153326740,"version":"4.0.1"},"reference-count":57,"publisher":"Bentham Science Publishers Ltd.","issue":"3","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/100000069","name":"NIH\/NIAMS trainee award","doi-asserted-by":"publisher","award":["T32 T32AR007603-15"],"award-info":[{"award-number":["T32 T32AR007603-15"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NIH\/NHLBI research award","doi-asserted-by":"publisher","award":["R01 HD052682"],"award-info":[{"award-number":["R01 HD052682"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2019,9,18]]},"abstract":"<jats:sec><jats:title>Background::<\/jats:title><jats:p>Pompe disease is a fatal neuromuscular disorder caused by a deficiency in acid \u03b1-glucosidase, an enzyme responsible for glycogen degradation in the lysosome. Currently, the only approved treatment for Pompe disease is enzyme replacement therapy (ERT), which increases patient survival, but does not fully correct the skeletal muscle pathology. Skeletal muscle pathology is not corrected with ERT because low cation-independent mannose-6-phosphate receptor abundance and autophagic accumulation inhibits the enzyme from reaching the lysosome. Thus, a therapy that more efficiently targets skeletal muscle pathology, such as adeno-associated virus (AAV), is needed for Pompe disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective::<\/jats:title><jats:p>The goal of this project was to deliver a rAAV9-coGAA vector driven by a tissue restrictive promoter will efficiently transduce skeletal muscle and correct autophagic accumulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods::<\/jats:title><jats:p>Thus, rAAV9-coGAA was intravenously delivered at three doses to 12-week old Gaa-\/- mice. 1 month after injection, skeletal muscles were biochemically and histologically analyzed for autophagy-related markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results::<\/jats:title><jats:p>At the highest dose, GAA enzyme activity and vacuolization scores achieved therapeutic levels. In addition, resolution of autophagosome (AP) accumulation was seen by immunofluorescence and western blot analysis of autophagy-related proteins. Finally, mice treated at birth demonstrated persistence of GAA expression and resolution of lysosomes and APs compared to those treated at 3 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion::<\/jats:title><jats:p>In conclusion, a single systemic injection of rAAV9-coGAA ameliorates vacuolar accumulation and prevents autophagic dysregulation.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1566523219666190621113807","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T13:20:11Z","timestamp":1561123211000},"page":"197-207","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5249-7176","authenticated-orcid":true,"given":"Angela L.","family":"McCall","sequence":"first","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6775-7564","authenticated-orcid":true,"given":"Sylvia G.","family":"Stankov","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-0410","authenticated-orcid":true,"given":"Gabrielle","family":"Cowen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1056-0090","authenticated-orcid":true,"given":"Denise","family":"Cloutier","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-5123","authenticated-orcid":true,"given":"Zizhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of Engineering, University of Florida, Gainesville, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7615-209X","authenticated-orcid":true,"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of Engineering, University of Florida, Gainesville, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0129-4368","authenticated-orcid":true,"given":"Nathalie","family":"Clement","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-7867","authenticated-orcid":true,"given":"Darin J.","family":"Falk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-1756","authenticated-orcid":true,"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1212\/WNL.23.1.95","volume":"23","author":"Engel A.G.","year":"1973","unstructured":"Engel A.G.; Gomez M.R.; Seybold M.E.; Lambert E.H.; The spectrum and diagnosis of acid maltase deficiency. Neuro 1973,23(1),95-106","journal-title":"Neuro"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1172\/JCI113008","volume":"79","author":"Reuser A.J.","year":"1987","unstructured":"Reuser A.J.; Kroos M.; Willemsen R.; Swallow D.; Tager J.M.; Galjaard H.; Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest 1987,79(6),1689-1699","journal-title":"J Clin Invest"},{"key":"ref=3","first-page":"132","volume":"30","author":"Reuser A.J.","year":"1978","unstructured":"Reuser A.J.; Koster J.F.; Hoogeveen A.; Galjaard H.; Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet 1978,30(2),132-143","journal-title":"Am J Hum Genet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1042\/bj0860011","volume":"86","author":"Hers H.G.","year":"1963","unstructured":"Hers H.G.; Alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe\u2019s disease). Biochem J 1963,86,11-16","journal-title":"Biochem J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.1002\/humu.20745","volume":"29","author":"Kroos M.","year":"2008","unstructured":"Kroos M.; Pomponio R.J.; van Vliet L.; Update of the pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 2008,29(6),E13-E26","journal-title":"Hum Mutat"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4161\/auto.6398","volume":"4","author":"Klionsky D.J.","year":"2008","unstructured":"Klionsky D.J.; Autophagy revisited: A conversation with Christian de Duve. Autophagy 2008,4(6),740-743","journal-title":"Autophagy"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1128\/EC.01.1.11-21.2002","volume":"1","author":"Reggiori F.","year":"2002","unstructured":"Reggiori F.; Klionsky D.J.; Autophagy in the eukaryotic cell. Eukaryot Cell 2002,1(1),11-21","journal-title":"Eukaryot Cell"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.4161\/auto.7.6.15812","volume":"7","author":"Mijaljica D.","year":"2011","unstructured":"Mijaljica D.; Prescott M.; Devenish R.J.; V-ATPase engagement in autophagic processes. Autoph 2011,7(6),666-668","journal-title":"Autoph"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1083\/jcb.110.6.1923","volume":"110","author":"Dunn W.A.","year":"1990","unstructured":"Dunn W.A.; Studies on the mechanisms of autophagy: Formation of the autophagic vacuole. J Cell Biol 1990,110(6),1923-1933","journal-title":"J Cell Biol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ana.20807","volume":"59","author":"Fukuda T.","year":"2006","unstructured":"Fukuda T.; Ewan L.; Bauer M.; Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol 2006,59(4),700-708","journal-title":"Ann Neurol"},{"key":"ref=11","first-page":"45","volume":"26","author":"Raben N.","year":"2007","unstructured":"Raben N.; Roberts A.; Plotz P.H.; Role of autophagy in the pathogenesis of Pompe disease. Acta Myol 2007,26(1),45-48","journal-title":"Acta Myol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02889849","volume":"45","author":"Griffin J.L.","year":"1984","unstructured":"Griffin J.L.; Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol 1984,45(1),23-36","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ymgme.2010.08.001","volume":"101","author":"Raben N.","year":"2010","unstructured":"Raben N.; Ralston E.; Chien Y-H.; Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: Implications for therapy. Mol Genet Metab 2010,101(4),324-331","journal-title":"Mol Genet Metab"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4161\/auto.4591","volume":"3","author":"Raben N.","year":"2007","unstructured":"Raben N.; Takikita S.; Pittis M.G.; Deconstructing Pompe disease by analyzing single muscle fibers: To see a world in a grain of sand. Autophagy 2007,3(6),546-552","journal-title":"Autophagy"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/cdd.2012.52","volume":"19","author":"Nascimbeni A.C.","year":"2012","unstructured":"Nascimbeni A.C.; Fanin M.; Masiero E.; Angelini C.; Sandri M.; The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ 2012,19(10),1698-1708","journal-title":"Cell Death Differ"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"Kishnani P.S.","year":"2007","unstructured":"Kishnani P.S.; Corzo D.; Nicolino M.; Recombinant human acid [alpha]-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology 2007,68(2),99-109","journal-title":"Neurology"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","volume":"14","author":"Fukuda T.","year":"2006","unstructured":"Fukuda T.; Ahearn M.; Roberts A.; Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther 2006,14(6),831-839","journal-title":"Mol Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","volume":"64","author":"Hagemans M.L.C.","year":"2005","unstructured":"Hagemans M.L.C.; Winkel L.P.F.; Hop W.C.J.; Reuser A.J.; Van Doorn P.A.; Van der Ploeg A.T.; Disease severity in children and adults with Pompe disease related to age and disease duration. Neuro 2005,64(12),2139-2141","journal-title":"Neuro"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.4161\/auto.6.8.13378","volume":"6","author":"Raben N.","year":"2010","unstructured":"Raben N.; Schreiner C.; Baum R.; Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease. Autoph 2010,6(8),1078-1089","journal-title":"Autoph"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1750-1172-8-90","volume":"8","author":"Prater S.N.","year":"2013","unstructured":"Prater S.N.; Patel T.T.; Buckley A.F.; Skeletal muscle pathology of infantile pompe disease during long-term enzyme replacement therapy. Orphanet J Rare Dis 2013,8(1),90","journal-title":"Orphanet J Rare Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6466","DOI":"10.1073\/pnas.81.20.6466","volume":"81","author":"Hermonat P.L.","year":"1984","unstructured":"Hermonat P.L.; Muzyczka N.; Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 1984,81(20),6466-6470","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1517\/17425247.2014.871258","volume":"11","author":"Wang D.","year":"2014","unstructured":"Wang D.; Zhong L.; Nahid M.A.; Gao G.; The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv 2014,11(3),345-364","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"14082","DOI":"10.1073\/pnas.93.24.14082","volume":"93","author":"Kessler P.D.","year":"1996","unstructured":"Kessler P.D.; Podsakoff G.M.; Chen X.; Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996,93(24),14082-14087","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/mt.2011.237","volume":"20","author":"Bowles D.E.","year":"2012","unstructured":"Bowles D.E.; McPhee S.W.J.; Li C.; Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012,20(2),443-455","journal-title":"Mol Ther"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","volume":"24","author":"Smith B.K.","year":"2013","unstructured":"Smith B.K.; Collins S.W.; Conlon T.J.; Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: Initial safety and ventilatory outcomes. Hum Gene Ther 2013,24(6),630-640","journal-title":"Hum Gene Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1093\/hmg\/ddr174","volume":"20","author":"Byrne B.J.","year":"2011","unstructured":"Byrne B.J.; Falk D.J.; Pacak C.A.; Pompe disease gene therapy. Hum Mol Genet 2011,20(R1),R61-R68","journal-title":"Hum Mol Genet"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"15007","DOI":"10.1038\/mtm.2015.7","volume":"2","author":"Falk D.J.","year":"2015","unstructured":"Falk D.J.; Soustek M.S.; Todd A.G.; Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice. Mol Ther Methods Clin Dev 2015,2,15007","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/hum.2015.103","volume":"27","author":"Doerfler P.A.","year":"2016","unstructured":"Doerfler P.A.; Todd A.G.; Cl\u00e9ment N.; Copackaged AAV9 vectors promote simultaneous immune tolerance and phenotypic correction of pompe disease. Hum Gene Ther 2016,27(1),43-59","journal-title":"Hum Gene Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S1046-2023(02)00220-7","volume":"28","author":"Zolotukhin S.","year":"2002","unstructured":"Zolotukhin S.; Potter M.; Zolotukhin I.; Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002,28(2),158-167","journal-title":"Methods"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/hum.2018.016","volume":"30","author":"Keeler A.M.","year":"2018","unstructured":"Keeler A.M.; Zieger M.; Todeasa S.; Systemic delivery of AAVB1-GAA clears glycogen and prolongs survival in a mouse model of Pompe disease. Hum Gene Ther 2018,30(1),57-68","journal-title":"Hum Gene Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1479-0556-6-13","volume":"6","author":"Pacak C.A.","year":"2008","unstructured":"Pacak C.A.; Sakai Y.; Thattaliyath B.D.; Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther 2008,6(1),13","journal-title":"Genet Vaccines Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/mtm.2016.31","volume":"3","author":"Adamson-Small L.","year":"2016","unstructured":"Adamson-Small L.; Potter M.; Falk D.J.; Cleaver B.; Byrne B.J.; Cl\u00e9ment N.; A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform. Mol Ther Methods Clin Dev 2016,3(3),16031","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hgtb.2016.151","volume":"28","author":"Adamson-Small L.","year":"2017","unstructured":"Adamson-Small L.; Potter M.; Byrne B.J.; Cl\u00e9ment N.; Sodium chloride enhances recombinant adeno-associated virus production in a serum-free suspension manufacturing platform using the herpes simplex virus system. Hum Gene Ther Methods 2017,28(1),1-14","journal-title":"Hum Gene Ther Methods"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1601-183x.2004.00064.x","volume":"3","author":"Bothe G.W.M.","year":"2004","unstructured":"Bothe G.W.M.; Bolivar V.J.; Vedder M.J.; Geistfeld J.G.; Genetic and behavioral differences among five inbred mouse strains commonly used in the production of transgenic and knockout mice. Genes Brain Behav 2004,3(3),149-157","journal-title":"Genes Brain Behav"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","volume":"273","author":"Raben N.","year":"1998","unstructured":"Raben N.; Nagaraju K.; Lee E.; Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 1998,273(30),19086-19092","journal-title":"J Biol Chem"},{"key":"ref=36","author":"Gombash Lampe S.E.","year":"2014","unstructured":"Gombash Lampe S.E.; Kaspar B.K.; Foust K.D.; Intravenous injections in neonatal mice. J Vis Exp 2014(93)","journal-title":"J Vis Exp"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0009-8981(73)90234-9","volume":"49","author":"Galjaard H.","year":"1973","unstructured":"Galjaard H.; Mekes M.; Josselin de Jong J.E.D.E.; Niermeijer M.F.; A method for rapid prenatal diagnosis of glycogenosis II (Pompe\u2019s disease). Clin Chim Acta 1973,49(3),361-375","journal-title":"Clin Chim Acta"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.3791\/51586","author":"Meng H.","year":"2014","unstructured":"Meng H.; Janssen P.M.L.; Grange R.W.; Tissue triage and freezing for models of skeletal muscle disease. J Vis Exp 2014(89)","journal-title":"J Vis Exp"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/jmi.12090","volume":"252","author":"Liu F.","year":"2013","unstructured":"Liu F.; Mackey A.L.; Srikuea R.; Esser K.A.; Yang L.; Automated image segmentation of haematoxylin and eosin stained skeletal muscle cross-sections. J Microsc 2013,252(3),275-285","journal-title":"J Microsc"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/sj.gt.3302550","volume":"12","author":"Mah C.","year":"2005","unstructured":"Mah C.; Cresawn K.O.; Fraites T.J.; Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther 2005,12(18),1405-1409","journal-title":"Gene Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/mt.2009.305","volume":"18","author":"Mah C.S.","year":"2010","unstructured":"Mah C.S.; Falk D.J.; Germain S.A.; Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 2010,18(3),502-510","journal-title":"Mol Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/jmor.1052210207","volume":"221","author":"Burkholder T.J.","year":"1994","unstructured":"Burkholder T.J.; Fingado B.; Baron S.; Lieber R.L.; Relationship between muscle fiber types and sizes and muscle architectural properties in the mouse hindlimb. J Morphol 1994,221(2),177-190","journal-title":"J Morphol"},{"key":"ref=43","first-page":"89","volume":"21","author":"Augusto V.","year":"2004","unstructured":"Augusto V.; Padovani C.R.; Campos G.E.R.; Skeletal Muscle Fiber Types in C57BL6J Mice. Braz J Morphol Sci 2004,21(2),89-94","journal-title":"Braz J Morphol Sci"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/ptj\/81.11.1810","volume":"81","author":"Scott W.","year":"2001","unstructured":"Scott W.; Stevens J.; Binder-Macleod S.A.; Human skeletal muscle fiber type classifications. Phys Ther 2001,81(11),1810-1816","journal-title":"Phys Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1152\/physrev.1972.52.1.129","volume":"52","author":"Close R.I.","year":"1972","unstructured":"Close R.I.; Dynamic mammalian properties of skeletal muscles. Physiol Rev 1972,52(1),129-197","journal-title":"Physiol Rev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10545-012-9541-7","volume":"36","author":"Van den Berg L.E.M.","year":"2013","unstructured":"Van den Berg L.E.M.; Drost M.R.; Schaart G.; Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype. J Inherit Metab Dis 2013,36(5),787-794","journal-title":"J Inherit Metab Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1113\/jphysiol.1983.sp014658","volume":"338","author":"Maughan R.J.","year":"1983","unstructured":"Maughan R.J.; Watson J.S.; Weir J.; Strength and cross-sectional area of human skeletal muscle. J Physiol 1983,338,37-49","journal-title":"J Physiol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"Mendell J.R.","year":"2017","unstructured":"Mendell J.R.; Al-Zaidy S.; Shell R.; Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017,377(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymthe.2017.12.011","volume":"26","author":"Kuntz N","year":"2018","unstructured":"Kuntz N; Shieh PB; Smith B; Abstract 7. Gene therapy trial in X-linked myotubular myopathy (Xlmtm): Preliminary safety and efficacy findings. Mol Ther (5S1)2018,26,4","journal-title":"Mol Ther"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4161\/auto.2984","volume":"2","author":"Fukuda T.","year":"2006","unstructured":"Fukuda T.; Roberts A.; Ahearn M.; Autophagy and lysosomes in pompe disease. Autophagy 2006,2(4),318-320","journal-title":"Autophagy"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015239","volume":"5","author":"Takikita S.","year":"2010","unstructured":"Takikita S.; Schreiner C.; Baum R.; Fiber type conversion by PGC-1\u03b1 activates lysosomal and autophagosomal biogenesis in both unaffected and Pompe skeletal muscle. PLoS One 2010,5(12)","journal-title":"PLoS One"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/humc.2017.146","volume":"28","author":"Corti M.","year":"2017","unstructured":"Corti M.; Liberati C.; Smith B.K.; Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by pompe disease. Hum Gene Ther Clin Dev 2017,28(4),146","journal-title":"Hum Gene Ther Clin Dev"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/sj.gt.3303029","volume":"14","author":"Bostick B.","year":"2007","unstructured":"Bostick B.; Ghosh A.; Yue Y.; Long C.; Duan D.; Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther 2007,14(22),1605-1609","journal-title":"Gene Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ana.24433","volume":"78","author":"Todd A.G.","year":"2015","unstructured":"Todd A.G.; McElroy J.A.; Grange R.W.; Correcting neuromuscular deficits with gene therapy in pompe disease. Ann Neurol 2015,78(2),222-234","journal-title":"Ann Neurol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1542\/peds.2007-2222","volume":"122","author":"Chien Y.H.","year":"2008","unstructured":"Chien Y.H.; Chiang S.C.; Zhang X.K.; Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008,122(1),e39-e45","journal-title":"Pediatrics"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","volume":"124","author":"Chien Y-H.Y-H.","year":"2009","unstructured":"Chien Y-H.Y-H.; Lee N-C.; Thurberg B.L.; Pompe disease in infants: Improving the prognosis by newborn screening and early treatment. Pediatrics 2009,124(6),e1116-e1125","journal-title":"Pediatrics"},{"key":"ref=57","first-page":"329","volume":"66","author":"Kishnani PS","year":"2009","unstructured":"Kishnani PS; Corzo D; Leslie ND; Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease Pediatr Res NIH Public Access 2009,66(3),329-5","journal-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease Pediatr Res NIH Public Access"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T04:42:04Z","timestamp":1609994524000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172917\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9,18]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523219666190621113807","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}